Overall, these data support the view that altering the TLR3 pathway, including increased TLR3 levels and downstream ligand induced activation, can potentially be exploited for cancer treatments utilizing existing mutants or WT p53 in combination with chemotherapeutic drugs. Here, TP53 is linked to cancer.